Sequel Pharmaceuticals is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing novel, clinical-stage drug candidates. Sequel intends to grow its drug portfolio through in-licensing of additional cardiovascular drug candidates.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 09/01/07 | Series A | 20M | Domain Associates, Forward Ventures, InterWest Partners, Montreux Equity Partners, Skyline Ventures | Unknown |
People
Stuart Collinson (Board Member)
David Lowe (Board Member)
Joseph Turner (Board Member)
Randall Woods (President/CEO)
Howard Dittrich (Chief Medical Officer)
View more details about all 12 people at Sequel Pharmaceuticals
News
Death Of A Thousand Pricks: Unboxing Dead Rising 2 Zombrex Edition
September 29, 2010 8:34 am
I love Dead Rising, and I'm making the responsible choice to protect myself and the ones I love, so that… Continue reading ⟩
PopCap Games executive interview: Don't be stupid, have fun
April 21, 2008 12:00 pm
If there is a hit factory in casual video games, it’s PopCap Games. While other companies drove the industry to… Continue reading ⟩
Life sciences briefing: Thursday, Jan. 3, 2008
January 4, 2008 2:49 am
TODAY’S HEADLINES: Gelesis draws in $16M for obesity treatments (release) Tempo Pharma raises $8B for nanoparticle drugs (release) Calistoga Pharma… Continue reading ⟩